Cornerstone Sues Exela Over Generic Hypertension Drug
Cornerstone's complaint asked the court for preliminary and permanent injunctions to stop Exela from developing and selling a generic version of Cornerstone’s drug, Cardene I.V. Premixed Injection, an intravenous, short-term treatment for hypertension that it markets as an alternative to oral therapy.
Exela sent Cornerstone a letter...
Already a subscriber? Click here to login